KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Other Non-Current Assets (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Other Non-Current Assets for 8 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets rose 9.99% year-over-year to $5.7 million, compared with a TTM value of $5.7 million through Dec 2025, up 9.99%, and an annual FY2025 reading of $5.7 million, up 9.99% over the prior year.
  • Other Non-Current Assets was $5.7 million for Q4 2025 at Biocryst Pharmaceuticals, up from $4.4 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $13.0 million in Q1 2024 and bottomed at $1.8 million in Q4 2023.
  • Average Other Non-Current Assets over 3 years is $6.5 million, with a median of $5.4 million recorded in 2024.
  • Peak annual rise in Other Non-Current Assets hit 185.86% in 2024, while the deepest fall reached 80.6% in 2024.
  • Year by year, Other Non-Current Assets stood at $1.8 million in 2023, then skyrocketed by 185.86% to $5.2 million in 2024, then rose by 9.99% to $5.7 million in 2025.
  • Business Quant data shows Other Non-Current Assets for BCRX at $5.7 million in Q4 2025, $4.4 million in Q3 2025, and $3.6 million in Q2 2025.